COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response

Open Heart. 2020 Jun;7(1):e001302. doi: 10.1136/openhrt-2020-001302.
No abstract available

Keywords: coronary artery disease; hypertension; risk factors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / virology
  • Enzyme Replacement Therapy* / adverse effects
  • Hemodynamics / drug effects*
  • Host-Pathogen Interactions
  • Humans
  • Pandemics
  • Peptidyl-Dipeptidase A / adverse effects
  • Peptidyl-Dipeptidase A / deficiency
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / therapeutic use*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / virology
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / genetics
  • SARS-CoV-2
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antiviral Agents
  • ACE protein, human
  • Peptidyl-Dipeptidase A